Humana (NYSE:HUM) Releases FY 2025 Earnings Guidance

Humana (NYSE:HUM) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 16.250-16.250 for the period, compared to the consensus estimate of 16.910. The company issued revenue guidance of -.

Humana Trading Down 2.7 %

Shares of HUM stock opened at $266.91 on Tuesday. Humana has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a 50-day simple moving average of $274.21 and a two-hundred day simple moving average of $297.52. The company has a market capitalization of $32.14 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 2.11 and a beta of 0.56. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Analysts Set New Price Targets

HUM has been the subject of a number of research reports. Wells Fargo & Company reduced their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and increased their target price for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Piper Sandler increased their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. TD Cowen increased their target price on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, Truist Financial increased their target price on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and an average price target of $297.68.

Insider Transactions at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.